SCHEDULE 13G/A: Soleus Entities Disclose Nearly 10% Passive Stake in Jasper Therapeutics

Soleus Capital Management, L.P. and its affiliated entities, including Soleus Private Equity Fund III, L.P. and Soleus Capital Master Fund, L.P., along with Guy Levy, have reported a combined beneficial ownership of 9.96% of Jasper Therapeutics, Inc.'s common stock as of December 31, 2024, in a passive Schedule 13G/A filing.

Summary

• Soleus Capital Management, L.P. and its affiliates, including Soleus Private Equity Fund III, L.P. and Soleus Capital Master Fund, L.P., along with Guy Levy, collectively reported beneficial ownership of 1,494,420 shares of Jasper Therapeutics, Inc. common stock.
• This aggregate ownership represents 9.96% of the Issuer's outstanding common stock.
• The percentage is calculated based on 15,001,353 shares of common stock outstanding as of November 6, 2024, as reported in Jasper Therapeutics' Quarterly Report on Form 10-Q filed on November 7, 2024.
• Soleus Private Equity Fund III, L.P. directly holds 200,000 shares, representing 1.3% of the class.
• Soleus Capital Master Fund, L.P. directly holds 1,294,420 shares, representing 8.6% of the class.
• All reporting persons disclaim beneficial ownership of these shares except for the purpose of determining their obligations under Section 13(d) of the Securities Exchange Act of 1934, indicating a passive investment intent.

Sentiment

Score: 5

Explanation: The document is a neutral, factual disclosure of beneficial ownership, providing no positive or negative operational or financial news about the issuer.

Future Outlook

NA

Industry Context

This filing is a standard disclosure of significant passive ownership by institutional investors in a publicly traded company, common across all industries. It does not provide specific insights into the biotechnology or pharmaceutical industry trends where Jasper Therapeutics operates.

Related Party Transactions

• The filing details the hierarchical relationship and control structure among the Soleus entities (Soleus Private Equity Fund III, L.P., Soleus Private Equity GP III, LLC, Soleus PE GP III, LLC, Soleus Capital Master Fund, L.P., Soleus Capital, LLC, Soleus Capital Group, LLC, Soleus Capital Management, L.P., Soleus GP, LLC) and Guy Levy, who is the sole managing member of key controlling entities. This structure defines how the beneficial ownership is shared and controlled within the Soleus group.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, which can influence market perception and potentially signal institutional confidence or interest in the company.
• Management: Awareness of a significant passive shareholder group, though the filing explicitly states the shares are not held for the purpose of changing or influencing control.

Key Dates

Keywords

Jasper Therapeutics, Soleus Capital Management, Soleus Private Equity Fund, Soleus Capital Master Fund, Guy Levy, SEC filing, Schedule 13G, beneficial ownership, common stock, institutional ownership, passive investment